Skip to main content

Monoclonal ANTIbody-targeted CARBon nanobues against cancer

Objective

ANTICARB attempts to exploit the advantages offered by a novel nanotechnology platform – carbon nanotubes – and apply them to a clinically established therapeutic modality – targeted antibody therapy – for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics. ANTICARB combines two emerging technologies, antibody and nanotube technology, in a way that will allow safe development of antibody-nanotube conjugates and explore their swift translation into a clinical oncology setting. By combining proven, clinically used, anti-cancer agents – antibodies – with a novel nanotechnology-based platform made of advanced nanomaterials, ANTICARB aims at enhancing the therapeutic potency of the antibody and establish a new paradigm for oncology therapeutics. The ability of carbon nanotube technology to transport antibodies into the tumor cell cytoplasm may lead to validation of specific intracellular targets for oncology. This objective will be reached by adopting a multidisciplinary approach and by bringing together expertise from the fields of drug delivery, molecular biology, chemistry, engineering, pharmacology and toxicology. The proposal capitalises on this industry-academia multidisciplinary and perfectly integrated team, whose expertise spans from advanced biotech to sophisticated nanotechnology.

Field of science

  • /engineering and technology/nanotechnology
  • /natural sciences/biological sciences/molecular biology
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology
  • /medical and health sciences/basic medicine/pharmacology and pharmacy
  • /medical and health sciences/basic medicine/toxicology
  • /engineering and technology/nanotechnology/nano-materials

Call for proposal

FP7-HEALTH-2007-A
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

University College London
Address
Gower Street
WC1E 6BT London
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 894 570
Administrative Contact
Greta Borg-Carbott (Ms.)

Participants (7)

UCB PHARMA SA
Belgium
EU contribution
€ 204 000
Address
Allee De La Recherche 60
1070 Bruxelles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Michael Eaton (Prof.)
NANOCYL SA
Belgium
EU contribution
€ 244 852
Address
Rue De L'essor 4
5060 Sambreville
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Nathalie Luizi (Ms.)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
EU contribution
€ 506 733
Address
Rue Michel Ange 3
75794 Paris
Activity type
Research Organisations
Administrative Contact
Béatrice Lazarus (Ms.)
UNIVERSITA DEGLI STUDI DI TRIESTE
Italy
EU contribution
€ 387 000
Address
Piazzale Europa 1
34127 Trieste
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Roberto Paoletti (Dr.)
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Germany
EU contribution
€ 300 125
Address
Ingolstadter Landstrasse 1
85764 Neuherberg
Activity type
Research Organisations
Administrative Contact
Juergen Ertel (Dr.)
PANEPISTIMIO IOANNINON
Greece
EU contribution
€ 207 168
Address
Panepistemioypole Panepistemio Ioanninon
45110 Ioannina
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Dimitris Emfietzoglou (Dr.)
SEROSCIENCE LTD
Hungary
EU contribution
€ 222 560
Address
Csabai Kapu 20
3529 Miskolc
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Janos Szebeni (Dr.)